Home > Insider Trading > Filing (0001415889-13-000024)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1374328	Bond Laboratories Inc.	BNLB.OB	Medicinal Chemicals & Botanical Products (2833)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1247604	T Jason Adelman	Cipher Capital Partners C/O Rothschild 1251 Avenue Of The Americas, Suite 936 New York NY 10020		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-12-28	4,202,260	$0.00	12,971,808	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Warrant	$0.30	2012-11-15	2015-11-15	667,083	667,083	Direct
Common Stock	Series C Convertible Preferred Stock	$0.00	2012-11-15		1,334,000	1,334,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2015-11-15	667,083	667,083	Direct
	1,334,000	1,334,000	Direct

Footnotes

The Reporting Person acquired the shares of Issuer's common stock ("Common Stock") for aggregate consideration of $50,000 in a privately negotiated transaction.
The Warrant contains a provision preventing the exercise of the Warrant if, as a result of such exercise, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 9.99% of the Issuer's Common Stock issued and outstanding.
Each share of Series C Convertible Preferred Stock ("Series C Preferred") is convertible into 40,000 shares of Common Stock.
The Series C Preferred is perpetual.
The Certificate of Designations, Preferences and Rights of the Series C Preferred contains a provision preventing the conversion of the Series C Preferred if, as a result of such conversion, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 4.99% of the Issuer's Common Stock issued and outstanding.